Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methotrexate - Therakind

Next Previous
Drug Profile

Methotrexate - Therakind

Alternative Names: Jylamvo; Methotrexate oral solution - Therakind

Latest Information Update: 31 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therakind
  • Developer Shorla Oncology; Therakind
  • Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Eye disorder therapies; Glutamates; Heart failure therapies; Pterins; Small molecules
  • Mechanism of Action Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Mycosis fungoides; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 29 Oct 2024 Registered for Juvenile rheumatoid arthritis (In adolescents, In children) in USA (PO)
  • 29 Oct 2024 Registered for Precursor cell lymphoblastic leukaemia-lymphoma (In adolescents, In children) in USA (PO)
  • 25 Dec 2023 Launched for Precursor cell lymphoblastic leukaemia-lymphoma (In adults) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top